This randomized phase III trial studies tamoxifen citrate or letrozole together with bevacizumab to see how well it works compared with tamoxifen citrate or letrozole alone in treating women with stage III or stage IV breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate* or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Monoclonal antibodies, such as bevacizumab, may help control breast cancer by stopping the growth of blood vessels to the tumor. It is not yet known whether giving hormone therapy is more effective with or without bevacizumab in treating advanced breast cancer.
Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer
I. To compare the progression-free survival of letrozole therapy alone with the combination of letrozole therapy plus bevacizumab as first-line treatment in women with estrogen- and/or progesterone-receptor-positive advanced breast cancer.
I. To compare the proportion of patients receiving letrozole alone, who remain progression-free at 6 and 12 months, to those receiving letrozole plus bevacizumab.
II. To compare the incidence of objective response (complete response [CR] + partial response [PR]) in patients receiving letrozole with and without bevacizumab, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, excluding patients with non-measurable disease.
III. To compare the incidence of clinical benefit (CR + PR + stable disease>= 6 months) in patients receiving letrozole with and without bevacizumab.
IV. To compare the duration of objective response in patients receiving letrozole with and without bevacizumab.
V. To compare the time to treatment failure in patients receiving letrozole with and without bevacizumab; time to treatment failure is defined as the interval from randomization until progression, toxicity, withdrawn consent or going onto non-protocol therapy.
VI. To compare the overall survival of patients receiving letrozole with and without bevacizumab, including the probability of survival until 36 months.
V. To compare toxicity levels between the bevacizumab arm and the arm without bevacizumab in both the letrozole-treated patients and in the tamoxifen-treated patients.
VI. To compare progression-free survival and overall survival of all patients receiving endocrine therapy with and without bevacizumab (by combining both letrozole and tamoxifen* patient subgroups).
I. To compare baseline and changes in serial levels of circulating endothelial cells and circulating tumor cells in patients treated with endocrine therapy alone or endocrine therapy plus bevacizumab, and to explore the relationship of these markers with progression free survival.
II. To conduct proteomic analysis of longitudinal samples from patients with advanced-stage disease undergoing hormonal therapy to define new serum-based biomarkers related to disease activity.
III. To identify biologic correlates that will predict progression-free survival (PFS) and response to therapy.
IV. To conduct pharmacogenomic assessment of candidate variants in the vascular endothelial growth factor (VEGF), cytochrome P450 system (CYP) family 2, subfamily D, polypeptide 6 (2D6), and CYP family 19 (CYP19) genes and evaluate their association with PFS and other study outcomes.
V. To identify single nucleotide polymorphisms (SNPs) associated with progression free survival in the genome-wide approach (GWAS).
VI. To identify factors other than chronological age that predict the risk of grade 3, 4 or 5 toxicity with bevacizumab and endocrine therapy by means of functional age assessment measures; the factors to be studied include: functional status, comorbid medical conditions, cognitive function, psychological state, social support and nutritional status.
VII. To perform an exploratory analysis of the ability of the other factors included in the functional age assessment (either individual or in combination), to predict the risk of grade 3, 4 or 5 toxicity.
VIII. To evaluate longitudinal changes in the parameters of the factors described in objective VI while on therapy.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
NOTE: The placebo-controlled portion of the study was canceled on 5-15-10.
ARM I: Patients receive endocrine therapy* (tamoxifen citrate or letrozole) orally (PO) once daily (QD) on days 1-21 and bevacizumab intravenously (IV) over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive endocrine therapy* (tamoxifen citrate or letrozole) PO QD on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up every 6 months for the first 2 years and then annually for up to 3 years.
Estrogen Receptor Positive Progesterone Receptor Positive Recurrent Breast Carcinoma Stage IIIB Breast Cancer Stage IV Breast Cancer Bevacizumab Letrozole Tamoxifen Endothelial Growth Factors Antibodies Immunoglobulins Antibodies, Monoclonal Immunoglobulin G Citric Acid
For females ages 18 years and up
© The Regents of the University of California